Dthera

Digital therapeutics startup Dthera Sciences was sunk by Alzheimer's drug failures, CMS reimbursement limitations
By Dave Muoio | 04:04 pm | April 01, 2021
Former CEO Ed Cox tells the story of Dthera Sciences and outlines how the digital therapeutics landscape has shifted since his company's heyday.
Digital therapeutics is on the map, but still hammering out tough questions
By Dave Muoio and Laura Lovett | 04:45 pm | September 27, 2019
Digital therapeutic stakeholders came together at this week's DTx East conference to discuss the state of digital health investment, developing successful business models, the need for robust data and more.
Digital therapeutics may not cause toxicity, but they're not entirely without risk
By Laura Lovett | 05:22 pm | September 25, 2019
Stakeholders at today's DTx East event in Boston discuss digital therapeutic risk assessment and management. 
FDA grants digital therapeutic for Alzheimer's symptoms Breakthrough Device designation
By Dave Muoio | 04:29 pm | August 23, 2018
As laid out in the 21st Century Cures Act, the Breakthrough Devices Program looks to streamline new medical technologies that offer improved treatment for serious diseases.